Cargando…

Development and characterisation of SMURF2-targeting modifiers

The C2-WW-HECT-domain E3 ubiquitin ligase SMURF2 emerges as an important regulator of diverse cellular processes. To date, SMURF2-specific modulators were not developed. Here, we generated and investigated a set of SMURF2-targeting synthetic peptides and peptidomimetics designed to stimulate SMURF2’...

Descripción completa

Detalles Bibliográficos
Autores principales: Manikoth Ayyathan, Dhanoop, Levy-Cohen, Gal, Shubely, Moran, Boutros-Suleiman, Sandy, Lepechkin-Zilbermintz, Veronica, Shokhen, Michael, Albeck, Amnon, Gruzman, Arie, Blank, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808752/
https://www.ncbi.nlm.nih.gov/pubmed/33430646
http://dx.doi.org/10.1080/14756366.2020.1871337
_version_ 1783636968412807168
author Manikoth Ayyathan, Dhanoop
Levy-Cohen, Gal
Shubely, Moran
Boutros-Suleiman, Sandy
Lepechkin-Zilbermintz, Veronica
Shokhen, Michael
Albeck, Amnon
Gruzman, Arie
Blank, Michael
author_facet Manikoth Ayyathan, Dhanoop
Levy-Cohen, Gal
Shubely, Moran
Boutros-Suleiman, Sandy
Lepechkin-Zilbermintz, Veronica
Shokhen, Michael
Albeck, Amnon
Gruzman, Arie
Blank, Michael
author_sort Manikoth Ayyathan, Dhanoop
collection PubMed
description The C2-WW-HECT-domain E3 ubiquitin ligase SMURF2 emerges as an important regulator of diverse cellular processes. To date, SMURF2-specific modulators were not developed. Here, we generated and investigated a set of SMURF2-targeting synthetic peptides and peptidomimetics designed to stimulate SMURF2’s autoubiquitination and turnover via a disruption of the inhibitory intramolecular interaction between its C2 and HECT domains. The results revealed the effects of these molecules both in vitro and in cellulo at the nanomolar concentration range. Moreover, the data showed that targeting of SMURF2 with either these modifiers or SMURF2-specific shRNAs could accelerate cell growth in a cell-context-dependent manner. Intriguingly, a concomitant cell treatment with a selected SMURF2-targeting compound and the DNA-damaging drug etoposide markedly increased the cytotoxicity produced by this drug in growing cells. Altogether, these findings demonstrate that SMURF2 can be druggable through its self-destructive autoubiquitination, and inactivation of SMURF2 might be used to affect cell sensitivity to certain anticancer drugs.
format Online
Article
Text
id pubmed-7808752
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78087522021-01-22 Development and characterisation of SMURF2-targeting modifiers Manikoth Ayyathan, Dhanoop Levy-Cohen, Gal Shubely, Moran Boutros-Suleiman, Sandy Lepechkin-Zilbermintz, Veronica Shokhen, Michael Albeck, Amnon Gruzman, Arie Blank, Michael J Enzyme Inhib Med Chem Research Paper The C2-WW-HECT-domain E3 ubiquitin ligase SMURF2 emerges as an important regulator of diverse cellular processes. To date, SMURF2-specific modulators were not developed. Here, we generated and investigated a set of SMURF2-targeting synthetic peptides and peptidomimetics designed to stimulate SMURF2’s autoubiquitination and turnover via a disruption of the inhibitory intramolecular interaction between its C2 and HECT domains. The results revealed the effects of these molecules both in vitro and in cellulo at the nanomolar concentration range. Moreover, the data showed that targeting of SMURF2 with either these modifiers or SMURF2-specific shRNAs could accelerate cell growth in a cell-context-dependent manner. Intriguingly, a concomitant cell treatment with a selected SMURF2-targeting compound and the DNA-damaging drug etoposide markedly increased the cytotoxicity produced by this drug in growing cells. Altogether, these findings demonstrate that SMURF2 can be druggable through its self-destructive autoubiquitination, and inactivation of SMURF2 might be used to affect cell sensitivity to certain anticancer drugs. Taylor & Francis 2021-01-12 /pmc/articles/PMC7808752/ /pubmed/33430646 http://dx.doi.org/10.1080/14756366.2020.1871337 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Manikoth Ayyathan, Dhanoop
Levy-Cohen, Gal
Shubely, Moran
Boutros-Suleiman, Sandy
Lepechkin-Zilbermintz, Veronica
Shokhen, Michael
Albeck, Amnon
Gruzman, Arie
Blank, Michael
Development and characterisation of SMURF2-targeting modifiers
title Development and characterisation of SMURF2-targeting modifiers
title_full Development and characterisation of SMURF2-targeting modifiers
title_fullStr Development and characterisation of SMURF2-targeting modifiers
title_full_unstemmed Development and characterisation of SMURF2-targeting modifiers
title_short Development and characterisation of SMURF2-targeting modifiers
title_sort development and characterisation of smurf2-targeting modifiers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808752/
https://www.ncbi.nlm.nih.gov/pubmed/33430646
http://dx.doi.org/10.1080/14756366.2020.1871337
work_keys_str_mv AT manikothayyathandhanoop developmentandcharacterisationofsmurf2targetingmodifiers
AT levycohengal developmentandcharacterisationofsmurf2targetingmodifiers
AT shubelymoran developmentandcharacterisationofsmurf2targetingmodifiers
AT boutrossuleimansandy developmentandcharacterisationofsmurf2targetingmodifiers
AT lepechkinzilbermintzveronica developmentandcharacterisationofsmurf2targetingmodifiers
AT shokhenmichael developmentandcharacterisationofsmurf2targetingmodifiers
AT albeckamnon developmentandcharacterisationofsmurf2targetingmodifiers
AT gruzmanarie developmentandcharacterisationofsmurf2targetingmodifiers
AT blankmichael developmentandcharacterisationofsmurf2targetingmodifiers